IDH mutation

Reevaluating Age as a Prognostic Marker in Molecularly Defined Lower-Grade Gliomas

This article examines how age, traditionally considered a high-risk factor in lower-grade gliomas, influences prognosis and treatment decisions in the molecular era, highlighting the importance of IDH mutation status.

Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit